spacer
home > epc > autumn 2002 > fat redistribution in hiv patients - an opportunity for drug manufacturers?
PUBLICATIONS
European Pharmaceutical Contractor

Fat Redistribution in HIV Patients - An Opportunity for Drug Manufacturers?

Fat redistribution, or lipodystrophy, is a complicated disorder of adipose (fat) tissue. There are two main classes of lipodystrophy: inherited lipodystrophies (genetically determined) and acquired lipodystrophies (for example HIV-associated). Historically, lipodystrophy was defined as the selective loss of fat from different regions of the body. This definition has changed, at least with regard to HIV-associated lipodystrophy. When being described in relation to HIV pathogenesis, lipodystrophy is now defined as 'selective fat loss or gain, with preserved body cell mass and weight'. In other words, the observation of abnormal peripheral subcutaneous fat wasting or fat accumulation in patients undergoing combination anti-retroviral therapy.

The global market for drug products to treat lipodystrophy is increasing in size. Epidemiology data are currently being collected for this syndrome, and an increasing amount of research is being conducted to determine the underlying causes of lipodystrophic disorders. Through awareness of this ongoing research, pharmaceutical companies can avoid both the potentially damaging impact of specific drug association and niche target patient groups with therapy combinations that either inhibit or limit the onset of this damaging disorder.

Figure 1 shows the historical development of lipodystrophy syndrome with respect to the introduction of monotherapy and combination therapy, with the consequent change in definition of the term lipodystrophy (revised from John et al 2001).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dheeraj Khiytani, HIV Analyst at Datamonitor

Dheeraj Khiytani's qualifications include an honours degree in Biochemistry from Imperial College and a PhD in HIV Research from the University of Warwick. While at Imperial, Dheeraj assisted Imperial College Laboratories in conducting forensic investigations. Other experience as an undergraduate included time as an assistant conducting research into inherited genetic disorders in Hong Kong.

Dheeraj's PhD concentrated on the structure and function of HIV-1 pre-integration complexes. This research has recently been published in the Journal of General Virology. He has presented papers at the 1999 International Congress of Virology, Sydney and at the European Conference on Experimental AIDS Research, 2001. Dheeraj is Datamonitor's lead HIV analyst and has written numerous HIV specific reports, monthly HIV updates and various briefs on the HIV market.

spacer
Dheeraj Khiytani's
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPI to showcase results from BioStreamline project developing novel biotherapeutics

CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners — Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI — will showcase the results and discuss the potential impact on overcoming some of the most significant shortcomings of the biologics supply chain.
More info >>

White Papers

Unmet Medical Needs? Impacted by unmet Life Sciences Staffing Needs?

Clinical Professionals

Whilst the majority of Clinical Professionals clients are working to discover and develop innovative, cost effective medicines that address unmet medical needs they are not impacting the unmet needs of training and developing new recruits into the pharma industry. The impact is highlighted within entry level Clinical Trial Administrators and Clinical Research Associates (CTA/CRA). In the past the Pharmaceutical industry had highly developed training programs for these sought after candidates. As the use of outsourcing models and CRO’s has increased and fewer Pharma businesses embark on their own R&D a substantial gap is developing in newly trained Life Science graduates entering the market to commence a career within R&D. As further financial cuts are made within R&D spend this already dire situation continues to escalate.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement